anti cd8  (Bio X Cell)

Journal: Science Advances

Article Title: CREBBP loss drives immune evasion by epigenetically silencing STING and MHC-I in small cell lung cancer

doi: 10.1126/sciadv.aef1693

Figure Lengend Snippet: ( A ) In vivo tumor growth of RP-sgCtrl and RP-sg Crebbp cells in nude mice, with quantification of tumor weights at the endpoint (n = 6 per group). ( B ) In vivo tumor growth of RP-sgCtrl and RP-sg Crebbp cells in C57BL/6 mice, with quantification of tumor weights at the endpoint (n = 6 per group). ( C ) In vivo tumor growth of RP-shCtrl and RP-sh Crebbp cells in nude mice, with quantification of tumor weights at the endpoint (n = 5 per group). ( D ) In vivo tumor growth of RP-shCtrl and RP-sh Crebbp cells in C57BL/6 mice, with quantification of tumor weights at the endpoint (n = 4 for RP-shNS, n = 5 for each RP-sh Crebbp cell). ( E to G ) Flow cytometry analysis of CD8 + T cell proportions (E), CD44 hi CD62L lo CD8+ T cell proportions (F), and IFNγ + CD8 + T cell proportions (G) in allograft tumors formed by RP-sgCtrl and RP-sg Crebbp cells in C57BL/6 mice. n = 6 per group. ( H ) In vivo growth of RP-sgCtrl and RP-sg Crebbp cells in C57BL/6 mice treated with IgG control or anti-CD8 antibodies, with quantification of tumor weights at the endpoint (n = 5 per group). ( I ) Flow cytometry analysis of apoptotic RP-OVA, RP-OVA-shCtrl, and RP-OVA-sh Crebbp -1 tumor cells, with or without co-culture with OT-1 CD8 + T cells. Quantification of the apoptotic tumor cell proportions is shown (right). [(A), (B), (C), (D), and (H)] Two-way ANOVA test for tumor growth curves and unpaired Student’s t test for tumor weights. *** P < 0.001; **** P < 0.0001. ns, not significant. Data were shown as mean ± SEM. [(E) to (G) and (I)] Unpaired Student’s t test; * P < 0.05; ** P < 0.01. Data were shown as mean ± SD.

Article Snippet: For CD8 + T cell blockade experiments, IgG1 isotype control (BE0088, Bio X Cell, RRID: AB_1107775) and anti-CD8 (BE0223, Bio X Cell, RRID: AB_2687706) antibodies were administered intraperitoneally at 100 μg per mouse one day before tumor cell inoculation, followed by a second dose immediately after cell injection, and then doses every 3 days.

Techniques: In Vivo, Flow Cytometry, Analysis, Control, Co-culture Assay, shRNA

Journal: The EMBO Journal

Article Title: CD137 agonists in mice suppress germinal center responses by increasing the immunosuppressive activity of follicular regulatory T-cells

doi: 10.1038/s44318-026-00900-2

Figure Lengend Snippet: ( A ) Number of FRCs on the dLNs of non-immunized and immunized mice treated with anti-CD137 or its isotype-matched control. ( B ) Expression (MFI) of CR2, ICAM1, and MAdCAM1 on FDCs ( n = 4 mice/group). ( C ) Gating strategy used to analyze FDCs on Fig. . ( D ) Number of Tfh and Treg cells on the dLNs of non-immunized and immunized mice treated with anti-CD137 or its isotype control ( n = 4 mice/group). ( E ) Number of Tfhs, Tfrs and Tregs in immunized mice for 4 and 7 days treated with anti-CD137 or its isotype-matched control ( n = 3–4 mice; 1 independent experiment). ( F ) Ratio Tfh/Tfrs at day 4 and 7 post-immunization ( n = 4 mice). ( G ) Quantification of the percentage of Tfhs, Tfrs, and Tregs in non-immunized or immunized mice treated with anti-CD137 1D8 mAb or its isotype-matched control ( n = 5 mice; 1 independent experiment). ( H ) Quantification of the percentage of Tfrs expressing low CD25 on the membrane (left graph) and ICOS + PD-1+ double-positive cells in mice immunized and treated with anti-CD137 or its isotype-matched control ( n = 3–4 mice/group; 1 independent experiment). ( I ) Quantification of the percentage of PD-1 + CD25+ double-positive Tregs in mice treated as in ( H ). ( J ) Quantification of the percentage of CD8-T cells in the LNs of mice treated with the anti-CD8β depleting antibody or its isotype control ( n = 3 mice/group; 1 independent experiment). ( K ) Quantification of the MFI of MHC-I expressed by DCs in mice injected with recombinant IL-12 (10 µg) and treated with neutralizing anti-IL12, anti-IFNγ or isotype control at days -1 and 1 ( n = 2–3 mice/group; 1 independent experiment). All quantitative data are shown as mean ± SD and analyzed using one-way ANOVA with multiple comparisons or Welch’s t -test.

Article Snippet: anti-CD8β , BioXCell , Clone Lyt3.2.

Techniques: Control, Expressing, Membrane, Injection, Recombinant

Journal: The EMBO Journal

Article Title: CD137 agonists in mice suppress germinal center responses by increasing the immunosuppressive activity of follicular regulatory T-cells

doi: 10.1038/s44318-026-00900-2

Figure Lengend Snippet: ( A ) Experimental workflow. Mice were immunized i.p with ovalbumin and injected with 100 µg of anti-CD8β depleting antibody (isotype-treated in gray; anti-CD137-treated in filled orange) or its isotype control (isotype-treated in black; anti-CD137-treated in unfilled orange) at days -1, 2, and 5. The graph shows the quantification of the GC B cells in the four groups of mice ( n = 4 mice/group; 1 independent experiment). ( B ) Quantification of the percentage of Tfh, Tregs and Tfrs ( n = 4 mice/group). ( C ) Experimental workflow. Mice were immunized s.c with ovalbumin and injected with anti-IL12p40 neutralizing antibody (isotype-treated in gray; anti-CD137-treated in filled orange) or its isotype-matched control (isotype-treated in black; anti-CD137-treated in unfilled orange) every 2–3 days starting the day before immunization. The graph shows the quantification of the GC B cells in the four groups of mice ( n = 4 mice/group; 1 independent experiment). ( D ) Quantification of the percentage of Tfh, Tregs and Tfrs in IL-12 neutralized mice ( n = 4 mice/group; 1 independent experiment). ( E ) Experimental workflow. Mice were immunized s.c with Ovalbumin and injected with anti-IFNγ neutralizing antibody (isotype-treated in gray; anti-CD137-treated in filled orange) or its isotype-matched control (isotype-treated in black; anti-CD137-treated in unfilled orange) every 2–3 days starting the day before immunization. Quantification of the percentage of GC B cells and IgG1 + class-switched B cells ( n = 4 mice/group; 1 independent experiment). All quantitative data show means ± SD and were analyzed using one-way ANOVA with multiple comparisons. .

Article Snippet: anti-CD8β , BioXCell , Clone Lyt3.2.

Techniques: Injection, Control

Journal: The EMBO Journal

Article Title: CD137 agonists in mice suppress germinal center responses by increasing the immunosuppressive activity of follicular regulatory T-cells

doi: 10.1038/s44318-026-00900-2

Figure Lengend Snippet: Reagents and tools table

Article Snippet: anti-CD8β , BioXCell , Clone Lyt3.2.

Techniques:

Journal: bioRxiv

Article Title: Tissue Injury and Biomaterial Treatment Modulate Tumor Growth and Response to Immunotherapy

doi: 10.64898/2026.02.02.703323

Figure Lengend Snippet: VML Injury Impacts Anti-Tumor CD8 + T Cell Response. (A) Flow cytometric profiling of CT26 tumor-infiltrating CD8 + T cells, (B) PD1 expression on CD8 + T cells, and (C) CT26 tumor-specific CD8 + T cells marked by AH1-loaded MHC class I tetramer in uninjured and VML injured mice. (D) Single-cell RNA-sequencing (scRNAseq) of CT26 tumor-infiltrating T cells from uninjured and VML injured mice. UMAP depicting main T cell clusters (e.g., CD8, CD4, Treg, unconventional). (E) T cell UMAP separated by tumor-reactive AH1-Tetramer + CD8 + T cells (top) and other T cells (bottom) colored by cells from uninjured (gray) and VML injured (green) mice. (F) Differential gene expression and (G, H) GSEA using Hallmark or (I) curated list of T cell-related pathways with top leading edge genes comparing tumor-reactive AH1-Tetramer + CD8 + T cells of uninjured and VML injured mice. (J) Intracellular cytokine staining following ex vivo stimulation of IFNγ-producing effector cell types in CT26 tumors of uninjured and VML injured mice. (Statistics) Bar graphs: mean±SD. Normally distributed data (Shapiro-Wilk test, α=0.05) was analyzed using an unpaired two-tailed student t-test ( A-C, J ). Results representative of at least 2 independent experiments ( A-C ). NS: Not significant p>0.05, * p<0.05, ** p<0.01. UMAP: Uniform manifold approximation and projection. GSEA: Gene set enrichment analysis.

Article Snippet: CD8 + T cells were depleted using αCD8β antibody (clone 53-5.8, BioXCell BE0223) delivered via IP injections at 5mg/kg body weight prepared in sterile dilution buffer ( InVivo Pure pH 7.0, BioXCell IP0070).

Techniques: Expressing, Single Cell, RNA Sequencing, Gene Expression, Staining, Ex Vivo, Two Tailed Test

Journal: bioRxiv

Article Title: Tissue Injury and Biomaterial Treatment Modulate Tumor Growth and Response to Immunotherapy

doi: 10.64898/2026.02.02.703323

Figure Lengend Snippet: VML Injury Impacts Distant Tumor Growth by Engaging a Shared Tumor-Draining Lymph Node (tdLN). (A) Flow cytometric profiling of CD8 + T cells in CT26 tdLN, including effector memory differentiation (CD44 hi CD62L - ) and (B, C) activation (CD25 + , NKG2D + ) in uninjured and VML-injured mice. (D) The bilateral VML injury (square) was modified to a unilateral procedure performed on either the ipsilateral (triangle) or contralateral (inverted triangle) quadriceps muscle relative to the tumor-bearing flank. CT26 tumor growth kinetics of uninjured and VML-injured (bi-, ipsi-, and contra-lateral) mice (n=9-10). (E) Survival curve (volume >1500mm 3 or severe involuting ulceration) of CT26 tumor-bearing mice with ipsi-versus contra-lateral VML injury. (F) Inhibition of lymphocyte LN egress using FTY720 HCl (25 μg/mouse). Representative flow cytometry plots and quantification of CD3 + T cells in peripheral blood (collected at survival endpoint) to confirm successful sequestration of lymphocytes in LN/spleen. (G) CT26 tumor growth kinetics of uninjured and ipsilateral VML-injured mice treated with vehicle (solid) or FTY720 HCl (dashed) (n=9-10). (Statistics) Tumor growth curves: mean±SEM. Bar graphs: mean±SD ( D, E display earliest survival timepoint). For 2 groups, normally distributed data (Shapiro-Wilk test, α=0.05) was analyzed using an unpaired two-tailed student t-test ( B, C ); otherwise, a non-parametric two-tailed Mann-Whitney test was used ( A ). For >2 groups, data was analyzed using an ordinary one-way ( D ) or two-way ANOVA ( F, G ) with Tukey’s multiple comparisons test (only relevant comparisons shown). Survival: Kaplan-Meier curve with Log-Rank Mantel-Cox test ( E ). Results representative of at least 2 independent experiments ( D, G ). NS: Not significant p>0.05, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

Article Snippet: CD8 + T cells were depleted using αCD8β antibody (clone 53-5.8, BioXCell BE0223) delivered via IP injections at 5mg/kg body weight prepared in sterile dilution buffer ( InVivo Pure pH 7.0, BioXCell IP0070).

Techniques: Activation Assay, Modification, Inhibition, Flow Cytometry, Two Tailed Test, MANN-WHITNEY

Journal: bioRxiv

Article Title: Tissue Injury and Biomaterial Treatment Modulate Tumor Growth and Response to Immunotherapy

doi: 10.64898/2026.02.02.703323

Figure Lengend Snippet: Biomaterial Injury Treatment-Induced Type-2 Immunity Also Develops in Tumor-Associated Tissues and Contributes to Delayed Tumor Growth. (A) Flow cytometric profiling of B and T lymphocytes, (b) Tregs (CD4 + FoxP3 + CD25 + ), and (C) CD8 + /Treg ratio in CT26 tumor-draining lymph nodes (tdLNs) of uninjured and VML-injured (untreated and ECM-treated) mice. (D) Frequency of IL4-eGFP + CD4 + T cells (TH2) in CT26 tdLNs of VML-injured (untreated and ECM-treated) 4Get mice. (E) Type-2 cytokine (IL4 and IL13) production by CD4 + T cells in CT26 tdLNs of uninjured and VML-injured (untreated and ECM-treated) mice following ex vivo cell stimulation. (F) Frequency of IL4-eGFP + SiglecF + eosinophils and CD4 + T cells in CT26 tumor-encapsulating adipose of VML-injured (untreated and ECM-treated) 4Get mice. (G) IL4 neutralization: CT26 tumor growth and survival curves of VML-injured (untreated and ECM-treated) mice treated with isotype (solid) or αIL4 antibody (1 mg/mouse initial dose followed by 0.5 mg/mouse maintenance) (dashed) (n=9-10). (Statistics) Tumor growth curves: mean±SEM. Bar graphs: mean±SD. For 2 groups, normally distributed data (Shapiro-Wilk test, α=0.05) was analyzed using an unpaired, two-tailed student t-test ( D, F ). For >2 groups, data was analyzed using an ordinary one-way ( A-C, E ) or two-way ( G - only D20 ) ANOVA with Tukey’s multiple comparisons test. Survival: Kaplan-Meier curve with Log-Rank Mantel-Cox test ( G ). NS: Not significant p>0.05, * p<0.05, ** p<0.01, *** p<0.001.

Article Snippet: CD8 + T cells were depleted using αCD8β antibody (clone 53-5.8, BioXCell BE0223) delivered via IP injections at 5mg/kg body weight prepared in sterile dilution buffer ( InVivo Pure pH 7.0, BioXCell IP0070).

Techniques: Ex Vivo, Cell Stimulation, Neutralization, Two Tailed Test